Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia

International Clinical Psychopharmacology

Volumn 13, Issue 3, 1998, Pages 141-145

  Spina, Edoardo ^a,b,c   Avenoso, Angela ^a   Facciolà, Gabriella ^a   Fabrazzo, Michele ^d   Monteleone, Palmiero ^d   Maj, Mario ^d   Perucca, Emilio ^e   Caputi, Achille P ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Centre of Mental Health   (Italy)

^c University of Naples ^*

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

Clozapine; CYP1A2; CYP2D6; Drug interaction; Fluoxetine; Negative symptoms; Schizophrenia

Indexed keywords

CLOZAPINE; FLUOXETINE; NORCLOZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG OXIDATION; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY;

EID: 0031852710     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199805000-00009     Document Type: Article

References (36)

1. Altamura AC, Moro AR, Percudani M (1994). Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinetics 26:201-214.
2. Andreasen NC (1983). Scale for the assessment of negative symptoms (SANS). Iowa: University of Iowa.
3. Andreasen NC (1984). Scale for the assessment of positive symptoms (SAPS). Iowa: University of Iowa.
4. Avenoso A, Spina E, Campo G, Facciolà G, Ferlito M, Zuccaro P, et al. (1997). Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 35:335-339.
5. Avenoso A, Facciolà G, Campo GM, Fazio A, Spina E (1998). Determination of clozapine, N-desmethylclozapine, and clozapine N-oxide in human plasma by reverse phase high-performance liquid chromatography with ultraviolet detection. J Chromatography, in press.
6. Baldessarini RJ, Frankenburg FR (1991). Clozapine, a novel antipsychotic agent. New Engl J Med 324:746-754.
7. Baumann P (1996). Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinetics 6:444-469.
8. Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, et al. (1994). Clozapine disposition covaries with the CYP1A2 activity determined by the caffeine test. Br J Clin Pharmacol 38:471-473.
9. Brosen K, Skielbo E (1991). Fluoxetine and norfluoxetine are potent inhibitors of P450IID6, the source of the sparteine/debrisoquine oxidation polymorhism. Br J Clin Pharmacol 32:136-137.
10. Brosen K, Skielbo E, Rasmussen BB, Poulsen HE, Loft S (1993). Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 45:1211-1214.
11. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A (1996). Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 153:1625-1627.
12. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG (1994). Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 151:123-125.
13. Centorrino F, Baldessarini RJ, Frankenburg F, Kando J, Volpicelli SA, Flood JG (1996). Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 153:820-822.
14. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992). The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 activity in human liver. Br J Clin Pharmacol 34:262-265.
15. Dahl ML, Llerena A, Bondesson U, Lindstrom L, Bertilsson L (1994). Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphism. Br J Clin Pharmacol 37:71-74.
16. Edge SC, Markowitz JS, DeVane CL (1997). Clozapine drug-drug interactions: a review of the literature. Hum Psychopharmacol 12:5-20.
17. Eggert AE, Crismon ML, Dorson PG (1994). Lack of effect of fluoxetine on plasma clozapine concentrations. J Clin Psychiatry 55:454-455.
18. Fischer V, Vogels B, Mauer T, Tynes R (1992). The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Therapeutics 260:1355-1360.
19. Goff D, Midha K, Brotman A, Waites M, Baldessarini RJ (1991). Elevation of plasma concentrations of haloperidol after addition of fluoxetine. Am J Psychiatry 148:790-792.
20. Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E (1995). A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 117:417-423.
21. Haring C, Fleishacker WW, Schett P, Kumpel C, Barnas C (1990). Influence of patient-related variables on clozapine plasma concentrations. Am J Psychiatry 147:1471-1475.
22. Hiemke C, Weighmann H, Dahmen N, Wetzel H, Muller H (1994). Elevated serum levels of clozapine after addition of fluvoxamine. J Clin Psychopharmacol 14:279-281.
23. Jann MW, Grimsley SR, Gray EC, Chang WH (1993). Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinetics 24:161-176.
24. Jerling M, Lindstrom L, Bondesson U, Bertilsson L (1994). Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Therapeutic Drug Monit 16:368-374.
25. Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y (1995). The effects of serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 40:481-485.
26. Lane RM (1996). Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 11 (Suppl 5):31-61.
27. Linnet K, Olesen OV (1997). Metabolism of clozapine by cDNA-expresed human cytochrome P450 isozymes. 2nd Congress of the European Association for Clinical Pharmacology and Therapeutics. Eur J Clin Pharmacol 52 (Suppl):416.
28. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM (1993). Inhibition by fluoxetine of cytochrome P4502D6 activity. Clin Pharmacol Therapeutics 53:401-409.
29. Pichini S, Pacifici R, Altieri I, Pellegrini M, Zuccaro P (1996). Stereoselective determination of fluoxetine and norfluoxetine enantiomers in plasma samples by high-performance liquid chromatography. J Liquid Chromatography 19:1927-1935.
30. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt, Brosen K (1995). Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 39:151-159.
31. Silver H, Nassar A (1992). Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo controlled study. Biol Psychiatry 31:698-704.
32. Simpson GM, Angus JWS (1970). Drug-induced extrapyramidal disorders. Acta Psychiatr Scand 212 (Suppl):11-19.
33. Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, et al. (1994). Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 9:281-285.
34. Spina E, Perucca E (1994). Newer and older antidepressants. A comparative review of drug interactions. CNS Drugs 2:479-497.
35. Szegedi A, Wiesner J, Hiemke C (1995). Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 14:141-143.
36. Von Moltke L, Greenblatt DJ, Cotreau-Bibbo M, Harmatz JS, Shader RI (1994). Inhibition of alprazolam metabolism in vitro: effects of the serotonin reuptake inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23-31.